Development of a prognostic model based on immunogenic cell death/ferroptosis-related genes and the study of TREX1 effects on prostate cancer cells

The three-gene IFRG-based prognostic model may serve as a promising prognostic biomarker for PCa, providing predictive value and novel insights into the complex interactions between IFRGs and PCa progression. Moreover, TREX1 was identified as a potential therapeutic target, offering new perspectives for prognostic assessment and the development of immunotherapy strategies in PCa.